Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
CONCLUSION: In this small, retrospective study of chronic CTD-ILD, RTX was not associated with changes in FVC% or corticosteroid-sparing effects. Controlled, prospective studies are needed to more confidently define the effects of RTX in CTD-ILD. (Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 296-304).
PMID: 26847096 [PubMed - in process]
Source: Sarcoidosis Vasculitis and Diffuse Lung Diseases - Category: Respiratory Medicine Tags: Sarcoidosis Vasc Diffuse Lung Dis Source Type: research
More News: Arthritis | Autoimmune Disease | Corticosteroid Therapy | CT Scan | Interstitial Lung Disease | PET Scan | Physiology | Pneumonia | Prednisone | Respiratory Medicine | Rheumatoid Arthritis | Rheumatology | Rituxan | Sarcoidosis | Study | Vasculitis | Women